The Wall Street Journal: New omicron-specific COVID booster expected to be approved before trial data is in
The Food and Drug Administration is expected to authorize new COVID-19 booster shots this week without a staple of its normal decision-making process: data from a study showing whether the shots were safe and worked in humans.